bumetanide has been researched along with Disease Models, Animal in 56 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report that the oxytocin-mediated neuroprotective γ-aminobutyric acid (GABA) excitatory-inhibitory shift during delivery is abolished in the valproate and fragile X rodent models of autism." | 7.80 | Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. ( Ben-Ari, Y; Brouchoud, C; Burnashev, N; Chazal, G; Eftekhari, S; Ferrari, DC; Khalilov, I; Lemonnier, E; Lozovaya, N; Nardou, R; Shahrokhi, A; Tsintsadze, T; Tsintsadze, V; Tyzio, R, 2014) |
| "There is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis." | 7.80 | A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. ( Brandt, C; Brunhofer, G; Erker, T; Feit, PW; Gabriel, M; Kaila, K; Lindfors, J; Löscher, W; Töllner, K; Töpfer, M, 2014) |
| "These results suggest that bumetanide protects focal cerebral ischemia-reperfusion injury in rat, which might through the inhibition of NKCC1." | 7.80 | Bumetanide protects focal cerebral ischemia-reperfusion injury in rat. ( He, Y; Huang, H; Huang, J; Ruan, L; Wang, G, 2014) |
| "Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia." | 5.62 | Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective. ( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021) |
| "After intracerebral hemorrhage (ICH), brain edema commonly occurs and can cause death." | 5.51 | Failure of bumetanide to improve outcome after intracerebral hemorrhage in rat. ( Aziz, JR; Brar, PS; Clark, JJA; Colbourne, F; Fedor, BA; Nadeau, CA; Wilkinson, CM, 2019) |
| "In rat pups with early-life seizures, field recordings from dorsal and ventral hippocampus and prefrontal cortex demonstrated marked increase in coherence as well as a decrease in voltage correlation at all bandwidths compared to controls while there were minimal differences in total power and relative power spectral densities." | 5.42 | Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide. ( Barry, J; Camp, D; Flynn, S; Hernan, AE; Holmes, GL; Tian, C, 2015) |
| " In pentylenetetrazole-induced acute seizures only BUM532 combined with a sub-effective dose of PB increased the seizure threshold." | 3.96 | Functional characterization of novel bumetanide derivatives for epilepsy treatment. ( Auer, T; Erker, T; Schreppel, P; Schwarzer, C, 2020) |
| " We hypothesized that NKCC1 is highly expressed on oligodendrocytes (OLs) and increases vulnerability to hypoxia-ischemia (HI) mediated white matter injury, and that the NKCC1 inhibitor bumetanide would be protective in a rodent PVL model." | 3.81 | Chloride cotransporter NKCC1 inhibitor bumetanide protects against white matter injury in a rodent model of periventricular leukomalacia. ( Hu, MY; Jackson, MC; Jantzie, LL; Jensen, FE; Maxwell, JR; Park, HK; Yu, J, 2015) |
| "We report that the oxytocin-mediated neuroprotective γ-aminobutyric acid (GABA) excitatory-inhibitory shift during delivery is abolished in the valproate and fragile X rodent models of autism." | 3.80 | Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. ( Ben-Ari, Y; Brouchoud, C; Burnashev, N; Chazal, G; Eftekhari, S; Ferrari, DC; Khalilov, I; Lemonnier, E; Lozovaya, N; Nardou, R; Shahrokhi, A; Tsintsadze, T; Tsintsadze, V; Tyzio, R, 2014) |
| "There is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis." | 3.80 | A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. ( Brandt, C; Brunhofer, G; Erker, T; Feit, PW; Gabriel, M; Kaila, K; Lindfors, J; Löscher, W; Töllner, K; Töpfer, M, 2014) |
| "These results suggest that bumetanide protects focal cerebral ischemia-reperfusion injury in rat, which might through the inhibition of NKCC1." | 3.80 | Bumetanide protects focal cerebral ischemia-reperfusion injury in rat. ( He, Y; Huang, H; Huang, J; Ruan, L; Wang, G, 2014) |
| "The obtained results provide further evidence that bumetanide may be beneficial for treating neonatal seizures, and that NKCC1 represents a potential target for antiepileptic interventions in the immature brain." | 3.75 | Bumetanide inhibits rapid kindling in neonatal rats. ( Mazarati, A; Sankar, R; Shin, D, 2009) |
| "Facial paralysis was induced in 32 Wistar rats that we then divided into 4 groups: group 1, control; group 2, bumetanide; group 3, dexamethasone; group 4, bumetanide and dexamethasone." | 1.62 | Effect of Bumetanide on Facial Nerve Regeneration in Rat Model. ( Adatepe, T; Akakın, D; Araz Server, E; Kalaycık Ertugay, Ç; Karagöz Köroğlu, A; Longur, ES; Orun, O; Yiğit, Ö, 2021) |
| "Neonatal seizures are the most frequent type of neurological emergency in newborn infants, often being a consequence of prolonged perinatal asphyxia." | 1.62 | Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective. ( Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W, 2021) |
| "After intracerebral hemorrhage (ICH), brain edema commonly occurs and can cause death." | 1.51 | Failure of bumetanide to improve outcome after intracerebral hemorrhage in rat. ( Aziz, JR; Brar, PS; Clark, JJA; Colbourne, F; Fedor, BA; Nadeau, CA; Wilkinson, CM, 2019) |
| "Controlling seizures remains a challenging issue for the medical community." | 1.51 | Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue. ( Carlen, PL; Chang, M; Dufour, S; Valiante, TA, 2019) |
| "Understanding the seizure-inducing mechanisms of TBI is of the utmost importance, because these seizures are often resistant to traditional first- and second-line anti-seizure treatments." | 1.46 | NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility. ( Cotrina, ML; Gu, S; He, X; Huang, JH; Liu, W; Nedergaard, M; Shapiro, LA; Wang, EW; Wang, F; Wang, W; Wang, X, 2017) |
| "Ischemia-reperfusion acute lung injury is characterized by increased vascular permeability, lung edema, and neutrophil sequestration." | 1.46 | Inhibition of Na-K-Cl cotransporter isoform 1 reduces lung injury induced by ischemia-reperfusion. ( Huang, KL; Lan, CC; Lin, HJ; Peng, CK; Tang, SE; Wu, CP; Yang, SS, 2017) |
| "In rat pups with early-life seizures, field recordings from dorsal and ventral hippocampus and prefrontal cortex demonstrated marked increase in coherence as well as a decrease in voltage correlation at all bandwidths compared to controls while there were minimal differences in total power and relative power spectral densities." | 1.42 | Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide. ( Barry, J; Camp, D; Flynn, S; Hernan, AE; Holmes, GL; Tian, C, 2015) |
| " Based on pharmacokinetic studies with bumetanide, which showed extremely rapid elimination and low brain penetration of this drug in rats, bumetanide was administered systemically with different dosing protocols, including continuous intravenous infusion." | 1.36 | Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. ( Brandt, C; Heuchert, N; Löscher, W; Nozadze, M; Rattka, M, 2010) |
| "Pretreatment with bumetanide (0." | 1.35 | Age- and dose-specific anticonvulsant action of bumetanide in immature rats. ( Mares, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (14.29) | 29.6817 |
| 2010's | 42 (75.00) | 24.3611 |
| 2020's | 6 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 2 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Lv, H | 1 |
| Shan, X | 1 |
| Zhu, T | 1 |
| Ma, B | 1 |
| Zhang, HT | 1 |
| Bambini-Junior, V | 1 |
| Zhang, T | 1 |
| Li, WG | 1 |
| Gao, X | 1 |
| Li, F | 1 |
| Auer, T | 1 |
| Schreppel, P | 2 |
| Erker, T | 4 |
| Schwarzer, C | 1 |
| Skorput, AG | 1 |
| Lee, SM | 1 |
| Yeh, PW | 1 |
| Yeh, HH | 1 |
| Longur, ES | 1 |
| Yiğit, Ö | 1 |
| Kalaycık Ertugay, Ç | 1 |
| Araz Server, E | 1 |
| Adatepe, T | 1 |
| Akakın, D | 1 |
| Orun, O | 1 |
| Karagöz Köroğlu, A | 1 |
| Johne, M | 1 |
| Römermann, K | 1 |
| Hampel, P | 1 |
| Gailus, B | 1 |
| Theilmann, W | 1 |
| Ala-Kurikka, T | 1 |
| Kaila, K | 2 |
| Löscher, W | 5 |
| Kim, HR | 1 |
| Rajagopal, L | 1 |
| Meltzer, HY | 1 |
| Martina, M | 1 |
| Mandai, S | 1 |
| Furukawa, S | 1 |
| Kodaka, M | 1 |
| Hata, Y | 1 |
| Mori, T | 1 |
| Nomura, N | 1 |
| Ando, F | 1 |
| Mori, Y | 1 |
| Takahashi, D | 1 |
| Yoshizaki, Y | 1 |
| Kasagi, Y | 1 |
| Arai, Y | 1 |
| Sasaki, E | 1 |
| Yoshida, S | 1 |
| Furuichi, Y | 1 |
| Fujii, NL | 1 |
| Sohara, E | 1 |
| Rai, T | 1 |
| Uchida, S | 1 |
| Zhang, J | 1 |
| Pu, H | 1 |
| Zhang, H | 1 |
| Wei, Z | 1 |
| Jiang, X | 1 |
| Xu, M | 1 |
| Zhang, L | 1 |
| Zhang, W | 1 |
| Liu, J | 1 |
| Meng, H | 1 |
| Stetler, RA | 1 |
| Sun, D | 1 |
| Chen, J | 1 |
| Gao, Y | 1 |
| Chen, L | 1 |
| Mu, XP | 1 |
| Wang, HB | 1 |
| Cheng, X | 1 |
| Yang, L | 1 |
| Sun, XY | 1 |
| Qu, HL | 1 |
| Zhao, SS | 1 |
| Zhou, ZK | 1 |
| Liu, TT | 1 |
| Xiao, T | 1 |
| Song, B | 1 |
| Jolkkonen, J | 1 |
| Zhao, CS | 1 |
| Amin, H | 1 |
| Marinaro, F | 1 |
| De Pietri Tonelli, D | 1 |
| Berdondini, L | 1 |
| Dargaei, Z | 1 |
| Bang, JY | 1 |
| Mahadevan, V | 1 |
| Khademullah, CS | 1 |
| Bedard, S | 1 |
| Parfitt, GM | 1 |
| Kim, JC | 1 |
| Woodin, MA | 1 |
| Shen, CH | 1 |
| Lin, JY | 1 |
| Chang, YL | 1 |
| Wu, SY | 1 |
| Peng, CK | 2 |
| Wu, CP | 2 |
| Huang, KL | 2 |
| Hoppe, K | 1 |
| Chaiklieng, S | 1 |
| Lehmann-Horn, F | 1 |
| Jurkat-Rott, K | 1 |
| Wearing, S | 1 |
| Klingler, W | 1 |
| Wilkinson, CM | 1 |
| Fedor, BA | 1 |
| Aziz, JR | 1 |
| Nadeau, CA | 1 |
| Brar, PS | 1 |
| Clark, JJA | 1 |
| Colbourne, F | 1 |
| Chang, M | 1 |
| Dufour, S | 1 |
| Carlen, PL | 1 |
| Valiante, TA | 1 |
| Cloarec, R | 1 |
| Riffault, B | 1 |
| Dufour, A | 1 |
| Rabiei, H | 1 |
| Gouty-Colomer, LA | 1 |
| Dumon, C | 1 |
| Guimond, D | 1 |
| Bonifazi, P | 1 |
| Eftekhari, S | 2 |
| Lozovaya, N | 2 |
| Ferrari, DC | 2 |
| Ben-Ari, Y | 2 |
| Takasu, K | 1 |
| Tateno, T | 1 |
| Yuan, Y | 1 |
| O'Malley, HA | 1 |
| Smaldino, MA | 1 |
| Bouza, AA | 1 |
| Hull, JM | 1 |
| Isom, LL | 1 |
| Zhu, Y | 1 |
| Zhang, XL | 1 |
| Gold, MS | 1 |
| Wu, F | 1 |
| Mi, W | 1 |
| Cannon, SC | 1 |
| Tyzio, R | 1 |
| Nardou, R | 1 |
| Tsintsadze, T | 1 |
| Shahrokhi, A | 1 |
| Khalilov, I | 1 |
| Tsintsadze, V | 1 |
| Brouchoud, C | 1 |
| Chazal, G | 1 |
| Lemonnier, E | 1 |
| Burnashev, N | 1 |
| Töllner, K | 3 |
| Brandt, C | 4 |
| Töpfer, M | 1 |
| Brunhofer, G | 1 |
| Gabriel, M | 1 |
| Feit, PW | 1 |
| Lindfors, J | 1 |
| Mesuret, G | 1 |
| Engel, T | 1 |
| Hessel, EV | 1 |
| Sanz-Rodriguez, A | 1 |
| Jimenez-Pacheco, A | 1 |
| Miras-Portugal, MT | 1 |
| Diaz-Hernandez, M | 1 |
| Henshall, DC | 1 |
| Wang, G | 1 |
| Huang, H | 1 |
| He, Y | 1 |
| Ruan, L | 1 |
| Huang, J | 1 |
| MacKenzie, G | 2 |
| Maguire, J | 2 |
| Jantzie, LL | 1 |
| Hu, MY | 1 |
| Park, HK | 1 |
| Jackson, MC | 1 |
| Yu, J | 1 |
| Maxwell, JR | 1 |
| Jensen, FE | 1 |
| Holmes, GL | 1 |
| Tian, C | 1 |
| Hernan, AE | 1 |
| Flynn, S | 1 |
| Camp, D | 1 |
| Barry, J | 1 |
| Deidda, G | 1 |
| Parrini, M | 1 |
| Naskar, S | 1 |
| Bozarth, IF | 1 |
| Contestabile, A | 1 |
| Cancedda, L | 1 |
| Hamidi, S | 1 |
| Avoli, M | 1 |
| Mòdol, L | 1 |
| Santos, D | 1 |
| Cobianchi, S | 1 |
| González-Pérez, F | 1 |
| López-Alvarez, V | 1 |
| Navarro, X | 1 |
| Tao, K | 1 |
| Ichikawa, J | 1 |
| Matsuki, N | 1 |
| Ikegaya, Y | 1 |
| Koyama, R | 1 |
| Twele, F | 1 |
| Schidlitzki, A | 1 |
| O'Toole, KK | 1 |
| Moss, SJ | 1 |
| Zhang, M | 1 |
| Cui, Z | 1 |
| Cui, H | 1 |
| Cao, Y | 1 |
| Zhong, C | 1 |
| Wang, Y | 1 |
| Wang, F | 1 |
| Wang, X | 1 |
| Shapiro, LA | 1 |
| Cotrina, ML | 1 |
| Liu, W | 1 |
| Wang, EW | 1 |
| Gu, S | 1 |
| Wang, W | 1 |
| He, X | 1 |
| Nedergaard, M | 1 |
| Huang, JH | 1 |
| Huang, YJ | 1 |
| Lee, KH | 1 |
| Murphy, L | 1 |
| Garraway, SM | 1 |
| Grau, JW | 1 |
| Lan, CC | 1 |
| Tang, SE | 1 |
| Lin, HJ | 1 |
| Yang, SS | 1 |
| Mazarati, A | 2 |
| Shin, D | 2 |
| Sankar, R | 2 |
| Mares, P | 1 |
| Nishimura, M | 1 |
| Kakigi, A | 1 |
| Takeda, T | 1 |
| Okada, T | 1 |
| Doi, K | 1 |
| Nozadze, M | 1 |
| Heuchert, N | 1 |
| Rattka, M | 1 |
| Auvin, S | 1 |
| Kwon, YS | 1 |
| Pineda, E | 1 |
| Wallace, BK | 1 |
| Foroutan, S | 2 |
| O'Donnell, ME | 2 |
| Barmashenko, G | 1 |
| Hefft, S | 1 |
| Aertsen, A | 1 |
| Kirschstein, T | 1 |
| Köhling, R | 1 |
| Liu, Y | 1 |
| Shangguan, Y | 1 |
| Barks, JD | 1 |
| Silverstein, FS | 1 |
| Krystal, AD | 1 |
| Sutherland, J | 1 |
| Hochman, DW | 1 |
| Vargas, E | 1 |
| Petrou, S | 1 |
| Reid, CA | 1 |
| Fukuda, A | 1 |
| Margineanu, DG | 1 |
| Klitgaard, H | 1 |
| Lu, KT | 1 |
| Wu, CY | 1 |
| Yen, HH | 1 |
| Peng, JH | 1 |
| Wang, CL | 1 |
| Yang, YL | 1 |
| Kilb, W | 1 |
| Sinning, A | 1 |
| Luhmann, HJ | 1 |
| Brillault, J | 1 |
| Lam, TI | 1 |
| Rutkowsky, JM | 1 |
| Taylor, RR | 1 |
| Nevill, G | 1 |
| Forge, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Placebo-controlled, Phase II Clinical Trial With a Cross-over Design Assessing Efficacy of a Single Dose of Bumetanide in Reducing Focal Attack Severity in Hypokalaemic Periodic Paralysis Assessed Using the McManis Protocol[NCT02582476] | Phase 2 | 12 participants (Anticipated) | Interventional | 2015-01-31 | Terminated (stopped due to Slow enrolment and end of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
56 other studies available for bumetanide and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder.
Topics: Animals; Autism Spectrum Disorder; Brain; Bumetanide; Disease Models, Animal; Mice; Mice, Inbred Str | 2022 |
Functional characterization of novel bumetanide derivatives for epilepsy treatment.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Brain; Bumetanide; Convulsants; Disease Models, Anima | 2020 |
The NKCC1 antagonist bumetanide mitigates interneuronopathy associated with ethanol exposure in utero.
Topics: Alcohol Drinking; Animals; Bumetanide; Cerebral Cortex; Disease Models, Animal; Female; Fetal Alcoho | 2019 |
Effect of Bumetanide on Facial Nerve Regeneration in Rat Model.
Topics: Animals; Bumetanide; Dexamethasone; Disease Models, Animal; Facial Paralysis; Nerve Regeneration; Pr | 2021 |
Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Topics: Animals; Animals, Newborn; Anticonvulsants; Asphyxia Neonatorum; Bumetanide; Disease Models, Animal; | 2021 |
Depolarizing GABA
Topics: Animals; Bumetanide; Cognitive Dysfunction; Disease Models, Animal; gamma-Aminobutyric Acid; Mice; P | 2021 |
Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy.
Topics: Animals; Bumetanide; Cell Differentiation; Cell Line; Disease Models, Animal; Diuretics; Furosemide; | 2017 |
Inhibition of Na
Topics: Animals; Blood-Brain Barrier; Brain; Brain Edema; Brain Injuries, Traumatic; Bumetanide; Disease Mod | 2017 |
Inhibition of Nkcc1 promotes axonal growth and motor recovery in ischemic rats.
Topics: Animals; Axons; Biotin; Brain Infarction; Brain Ischemia; Brain-Derived Neurotrophic Factor; Bumetan | 2017 |
Developmental excitatory-to-inhibitory GABA-polarity switch is disrupted in 22q11.2 deletion syndrome: a potential target for clinical therapeutics.
Topics: Animals; Bumetanide; DiGeorge Syndrome; Disease Models, Animal; gamma-Aminobutyric Acid; Hippocampus | 2017 |
Restoring GABAergic inhibition rescues memory deficits in a Huntington's disease mouse model.
Topics: Animals; Bumetanide; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Hippocampus; Humans; H | 2018 |
Inhibition of NKCC1 Modulates Alveolar Fluid Clearance and Inflammation in Ischemia-Reperfusion Lung Injury via TRAF6-Mediated Pathways.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Bumetanide; Cell Line; Disease Models, Ani | 2018 |
Elevation of extracellular osmolarity improves signs of myotonia congenita in vitro: a preclinical animal study.
Topics: Animals; Bumetanide; Disease Models, Animal; Female; Male; Membrane Potentials; Mice; Muscle, Skelet | 2019 |
Failure of bumetanide to improve outcome after intracerebral hemorrhage in rat.
Topics: Animals; Bumetanide; Cerebral Hemorrhage; Chlorides; Collagenases; Disease Models, Animal; Male; Mas | 2019 |
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue.
Topics: Action Potentials; Animals; Bumetanide; Disease Models, Animal; Humans; Magnesium; Mice, Inbred C57B | 2019 |
Pyramidal neuron growth and increased hippocampal volume during labor and birth in autism.
Topics: Animals; Animals, Newborn; Autism Spectrum Disorder; Bumetanide; Dendrites; Disease Models, Animal; | 2019 |
In vivo transcranial flavoprotein autofluorescence imaging of tonotopic map reorganization in the mouse auditory cortex with impaired auditory periphery.
Topics: Acoustic Stimulation; Animals; Auditory Cortex; Auditory Threshold; Brain Mapping; Bumetanide; Disea | 2019 |
Delayed maturation of GABAergic signaling in the Scn1a and Scn1b mouse models of Dravet Syndrome.
Topics: Animals; Bumetanide; Death, Sudden; Disease Models, Animal; Epilepsies, Myoclonic; Epilepsy; gamma-A | 2019 |
Activity-dependent hyperpolarization of EGABA is absent in cutaneous DRG neurons from inflamed rats.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Action Potentials; Amino Acids; Animals; Bumetanid | 2014 |
Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.
Topics: Acetazolamide; Animals; Arginine; Bumetanide; Calcium Channels, L-Type; Carbonic Anhydrase Inhibitor | 2013 |
Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.
Topics: Animals; Autistic Disorder; Behavior, Animal; Bumetanide; Chlorides; Cytoprotection; Disease Models, | 2014 |
A novel prodrug-based strategy to increase effects of bumetanide in epilepsy.
Topics: Action Potentials; Animals; Animals, Newborn; Brain; Bumetanide; Convulsants; Disease Models, Animal | 2014 |
P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage.
Topics: Amygdala; Animals; Animals, Newborn; Bumetanide; Cell Death; Disease Models, Animal; Disease Progres | 2014 |
Bumetanide protects focal cerebral ischemia-reperfusion injury in rat.
Topics: Animals; Brain Ischemia; Bumetanide; Cerebral Cortex; Disease Models, Animal; Injections, Intravenou | 2014 |
Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models.
Topics: Animals; Anticonvulsants; Basolateral Nuclear Complex; Bumetanide; Disease Models, Animal; Drug Syne | 2015 |
Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility.
Topics: Acute Disease; Animals; Bumetanide; Chronic Disease; Corticosterone; Disease Models, Animal; gamma-A | 2015 |
Chloride cotransporter NKCC1 inhibitor bumetanide protects against white matter injury in a rodent model of periventricular leukomalacia.
Topics: Animals; Bumetanide; Cerebral Cortex; Disease Models, Animal; Gene Expression Regulation; Hypoxia; I | 2015 |
Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Brain; Bumetanide; Cell Count; Disease | 2015 |
Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.
Topics: Adolescent; Adult; Animals; Behavior, Animal; Bumetanide; Crosses, Genetic; Disease Models, Animal; | 2015 |
KCC2 function modulates in vitro ictogenesis.
Topics: 4-Aminopyridine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Bumetanide; Cerebral Cortex; Disease | 2015 |
NKCC1 Activation Is Required for Myelinated Sensory Neurons Regeneration through JNK-Dependent Pathway.
Topics: Animals; Animals, Newborn; Bumetanide; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; F | 2015 |
Experimental febrile seizures induce age-dependent structural plasticity and improve memory in mice.
Topics: Aging; Animals; Bumetanide; Disease Models, Animal; Fever; Hippocampus; Memory; Mice; Neurogenesis; | 2016 |
The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.
Topics: Animals; Anticonvulsants; Bumetanide; Convulsants; Disease Models, Animal; Dose-Response Relationshi | 2016 |
Compromised GABAergic inhibition contributes to tumor-associated epilepsy.
Topics: Animals; Brain; Brain Neoplasms; Bumetanide; Cell Line, Tumor; Disease Models, Animal; Epilepsy; gam | 2016 |
Astaxanthin alleviates cerebral edema by modulating NKCC1 and AQP4 expression after traumatic brain injury in mice.
Topics: Animals; Aquaporin 4; Brain; Brain Edema; Brain Injuries, Traumatic; Bumetanide; Capillary Permeabil | 2016 |
NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility.
Topics: Ammonia; Animals; Animals, Newborn; Bumetanide; Cell Count; Cerebral Cortex; Disease Models, Animal; | 2017 |
Acute spinal cord injury (SCI) transforms how GABA affects nociceptive sensitization.
Topics: Acetates; Analysis of Variance; Animals; Bicuculline; Bumetanide; Capsaicin; Disease Models, Animal; | 2016 |
Inhibition of Na-K-Cl cotransporter isoform 1 reduces lung injury induced by ischemia-reperfusion.
Topics: Acute Disease; Animals; Bumetanide; Capillary Permeability; Disease Models, Animal; Lung Injury; Mal | 2017 |
Bumetanide inhibits rapid kindling in neonatal rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Bumetanide; Disease Models, Animal; Electric Stimulation | 2009 |
Age- and dose-specific anticonvulsant action of bumetanide in immature rats.
Topics: Age Factors; Aging; Animals; Anticonvulsants; Bumetanide; Disease Models, Animal; Dose-Response Rela | 2009 |
Bumetanide-induced enlargement of the rat intrastrial space and effects of a vasopressin type 2 antagonist.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; | 2010 |
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
Topics: Amygdala; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Bumetanide; Cell Count; | 2010 |
Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling.
Topics: Age Factors; Animals; Animals, Newborn; Anticonvulsants; Bumetanide; Carbamates; Disease Models, Ani | 2010 |
Ischemia-induced stimulation of Na-K-Cl cotransport in cerebral microvascular endothelial cells involves AMP kinase.
Topics: Adenylate Kinase; Animals; Arginine Vasopressin; Blood-Brain Barrier; Blotting, Western; Bumetanide; | 2011 |
Positive shifts of the GABAA receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Analysis of Variance; Animals; Bi | 2011 |
Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal hypoxia-ischemia model.
Topics: Animals; Animals, Newborn; Bumetanide; Disease Models, Animal; Drug Synergism; Hypothermia, Induced; | 2012 |
Loop diuretics have anxiolytic effects in rat models of conditioned anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Bumetanide; Disease Models, Animal; Furosemide; Male; Rats; R | 2012 |
Genetic and pharmacological modulation of giant depolarizing potentials in the neonatal hippocampus associates with increased seizure susceptibility.
Topics: Animals; Animals, Newborn; Bumetanide; Disease Models, Animal; Epilepsy; Hippocampus; Mice; Mice, In | 2013 |
Diuretic soothes seizures in newborns.
Topics: Animals; Bumetanide; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Infant, Newbo | 2005 |
Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy.
Topics: Animals; Anticonvulsants; Bumetanide; Disease Models, Animal; Diuretics; Dose-Response Relationship, | 2006 |
Bumetanide administration attenuated traumatic brain injury through IL-1 overexpression.
Topics: Analysis of Variance; Animals; Brain Edema; Brain Injuries; Bumetanide; Disease Models, Animal; Hipp | 2007 |
Model-specific effects of bumetanide on epileptiform activity in the in-vitro intact hippocampus of the newborn mouse.
Topics: Animals; Animals, Newborn; Bumetanide; Chloride Channels; Disease Models, Animal; Epilepsy; Hippocam | 2007 |
Hypoxia effects on cell volume and ion uptake of cerebral microvascular endothelial cells.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Edema; Bumetanide; Cattle; Cell Hypoxia; Cell Size; Cells | 2008 |
Rapid hair cell loss: a mouse model for cochlear lesions.
Topics: Age Factors; Amikacin; Animals; Anti-Bacterial Agents; Bumetanide; Cell Death; Cell Survival; Cochle | 2008 |